CD4+ T Cells Market: Competitive Landscape, Pipeline, and Market Analysis 2023

Purchase Option

$ 4400
$ 6600
$ 8900

CD4 cells or CD4+ T helper cells, which stands for Cluster of Differentiation 4, are glycoproteins present on the surface of immune cells such as T  helper cells, macrophages, monocytes, and dendritic cells. Our immune system is unique in the sense that it keeps a record of all the pathogens that it has encountered and develops antibodies against the pathogen. These cells are responsible for maintaining an effective response to the pathogens. These get activated after interaction with an anti-MHC complex which then differentiates into specific subtypes depending on the cytokine present in the environment. This post-activation secretes cytokines mediating the effect. These cells carry out many functions, including activation of B-lymphocytes, cytotoxic T cells, immune system, and nonimmune cells. These also play a role in the suppression of immune reactions. Average CD4+ count in an individual range from 500 – 1500 cells/mm3. However, this count decreases to a very low value when a person is infected with diseases like HIV/AIDS. Hence, the reduced cell count is a diagnostic indication for AIDS. Extensive research is being conducted globally to discover new and novel molecules to be used as immunomodulators that function to decrease the number of activated T cells. The development and launch of new products will thus increase the market’s revenue in the forecasted years. The count is aberrant in autoimmune diseases such as Rheumatoid Arthritis (RA), Systemic Lupus Erythromaticus (SLE), Inflammatory Bowel Disease (IBD), Plaque Psoriasis, and others. Arthritis Foundation estimates the global prevalence of RA to be 0.5% to 1% in developed countries. Females are affected more than males, with 75% being females.

A number of these inhibitors are in the market, while many are in ongoing clinical trials. Many companies have various products in their pipelines, with 48 products in different stages of clinical trials. 3 products in Phase 4, 2 in Phase 3, 11 in Phase 2, and 10 in Phase 1 of the clinical trials.

Key Developments of CD4+ T Cells

  • In May 2023, FDA approved the 1st topical novel chemical entity in the USA - Vtama (tapinarof) cream, 1% for treating Plaque Psoriasis in adults.
  • In January 2022, Orencia (abatacept) became the 1st drug to be approved by the FDA for the prophylaxis of acute graft vs. host disease, in combination with Methotrexate and a Calcineurin inhibitor, in adults and pediatric patients two years of age and older undergoing hematopoietic stem cell transplantation from a matched or one allele-mismatched unrelated donor.

Approved molecules of CD4+ T Cells

  • Thymoglobulin (anti-thymocyte globulin (rabbit))
  • Orencia (abatacept)
  • Vtama (tapinarof)

Drugs in the Pipeline of CD4+ T Cells

  • VRC01
  • rhIL-15
  • HuMax-CD4 (zanolimumab)
  • Lupuzor (rigerimod)
  • Resolaris (resokine)
  • VRC01LS
  • tregalizumab (BT-061)
  • Tcelna (imilecleucel-T)
  • VTP-300
  • AGT103-T
  • AMP-110
  • BAT6026
  • CN1
  • HepTcell (FP-02.2)
  • MTRX 1011A
  • HFB200301
  • IMA203CD8
  • IMCY-0141
  • JCXH-212
  • MazF gene therapy
  • NG-348
  • RTL 1000
  • combinectin (GSK3732394)

Clinical Activity and Developments of CD4+ T Cells

As of June 2023, various companies have approximately 48 products for 768 diseases. For these diseases, many trials are being conducted by players globally. For instance,

  • In January 2023, the National Institute of Allergy and Infectious Diseases (NIAID) completed a Phase 4 clinical trial to evaluate SARS-CoV-2 immune responses after COVID-19 therapy and subsequent vaccine.
  • In October 2022, St George's, University of London conducted a Phase 4 clinical trial to compare Abatacept with Tumor Necrosis Factor Inhibitors in treating Rheumatoid Arthritis pain.
  • In March 2022, University Medical Center Groningen completed a Phase 4 clinical trial to study optimal repeated dose strategy for SARS-CoV-2 vaccination in kidney transplant patients.
  • Dermavant Sciences, Inc. is conducting a Phase 4 clinical trial to investigate the efficacy and safety of VTAMA® (Tapinarof) cream 1% in the treatment of Plaque Psoriasis in intertriginous areas that were expected to complete by June 2023.

Molecule name

Number of studies

Thymoglobulin (anti-thymocyte globulin (rabbit))


Orencia (abatacept)


Vtama (tapinarof)






Target Indication Analysis of CD4+ T Cells

Drugs like Orencia (abatacept) and Vtama (tapinarof) have been approved by the FDA and other regulatory agencies to treat various diseases. Orencia (abatacept) has been approved for use in adult patients suffering from moderate to severe Rheumatoid Arthritis (RA), while Vtama (tapinarof) is used for adult patients suffering from Plaque Psoriasis. These drugs act as immunosuppressants which depress the activation of T cells in the body, preventing disease symptoms. These have been approved for use as immunosuppressants in many diseases like Connective tissue diseases, various types of lymphomas and carcinomas, Sclerosis, Psoriasis, Systematic Lupus Erythromaticus (SLE), Papulosquamous skin diseases, Ulcerative colitis, and many others. These have shown promising results in clinical trials and have sought approval for various indications by regulatory agencies globally.

Frequently Asked Questions

Thymoglobulin (anti-thymocyte globulin (rabbit)), Orencia (abatacept), and Vtama (tapinarof) are approved by various regulatory agencies.

These are used to treat Plaque Psoriasis, Rheumatoid Arthritis, Systematic Lupus Erythromaticus (SLE), Papulosquamous skin diseases, Ulcerative colitis, and many others.

Sanofi, BMS, Roivant, and Japan Tobacco are some of the major market players for CD4+ T cells.

Rising incidence of diseases, development of new treatment lines in the market, and changing lifestyles leading to various diseases like Rheumatoid Arthritis, Plaque Psoriasis, and Systemic Lupus Erythromaticus are the key opportunities for CD4+ T cells in the market.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  • Sanofi
  • Bms
  • Roivant
  • Japan Tobacco
  • Acuitas Therapeutics
  • National Cancer Institute
  • Emergent Biosolutions
  • Immupharma
  • Alora Pharma
  • Atyr Pharma
  • National Institutes Of Health
  • Xencor
  • Adma Biologics
  • T-Balance Therapeutics
  • Acer Therapeutics
  • Emd Serono
  • Vaccitech
  • American Gene Technologies
  • Astrazeneca
  • Daiichi Sankyo
  • Bio-Thera Solutions
  • Curon Biopharma
  • Altimmune
  • Tolerx
  • Roche
  • Hifibio
  • Immatics
  • Imcyse
  • Immorna
  • Takara
  • Akamis Bio
  • Artielle
  • Viiv Healthcare
  • Gsk

Adjacent Markets